All members of PHO IAP were invited to join InPHOG and asked to specify their areas of research interest and 21 subcommittees (later expanded to 26) encompassing all areas were formed. A roadmap for the development and conduct of an InPHOG study was created. Over the next 6 years InPHOG had a portfolio of 31 studies with 10 017 children with cancer enrolled in nearly 23 clinical trials, 6944 [69.3%] patients in observational studies and 3073 [30.7%] of patients in interventional studies in 114 different institutions across the country.
In 2019, to enable the research wing to grow it was decided to have InPHOG as a separate entity as a section 8 company. Further benign hematological disorders were added to its remit and the name was changed to Indian Pediatric Hematology Oncology Group (INPHOG). INPHOG Research Foundation was incorporated as a Section 8 company on 22nd Dec 2021.
PHO Chapter of India and INPHOG continue to work together in their goals of making a positive impact on the lives of children with blood and cancer disorders in India. Joint meetings are held between PHO executive board and INPHOG board. PHO Chapter, the parent body of all pediatric hematologists and oncologists in India endeavours to provide full support to INPHOG to further research in this niche specialty in the country.